Skip to main content

Advertisement

SpringerLink
Log in

Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma

  • Short Communication
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Patients with metastatic renal cell carcinoma (mRCC) are often treated sequentially with targeted agents, although the optimal strategy is not known. A retrospective, registry-based study has been carried out to assess correlation between clinical response and progression-free survival in patients with mRCC treated sequentially with tyrosine-kinase inhibitors (TKIs) sunitinib and sorafenib. Data on 218 mRCC patients treated with sunitinib and sorafenib who completed therapy with both TKIs were obtained from a database of mRCC patients. Standard nonparametric methods were used to assess correlation between response, PFS and length of treatment on the two agents. A strong correlation between responses to first- versus second TKI was observed (p < 0.001). No significant association was noted between the duration of therapy with the two TKIs (p = 0.056), although there was a weak statistically significant correlation between progression-free survival times in the subgroup patients who discontinued treatment because of disease progression. In conclusion, the duration of response on first TKI is of limited value in selecting mRCC patients for sequential TKI therapy. There is a strong correlation between the types of tumour response on the first- versus the second TKI.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372:449–56.

    Article  PubMed  CAS  Google Scholar 

  2. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378:1931–9.

    Article  PubMed  CAS  Google Scholar 

  3. Buchler T, Klapka R, Melichar B, Brabec P, Dusek L, Vyzula R, Abrahamova J. Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma—data from the Czech registry. Ann Oncol. 2012;23:395–401.

    Article  PubMed  CAS  Google Scholar 

  4. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–24.

    Article  PubMed  CAS  Google Scholar 

  5. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125–34.

    Article  PubMed  CAS  Google Scholar 

  6. Al-Marrawi MY, Rini BI, Harshman LC, Bjarnason GA, Wood L, Vaishampayan UN, MacKenzie MJ, Knox JJ, Agarwal N, Kollmannsberger CK, Tan M, Rha SY, Donskov F, North SA, Choueiri TK, Heng DYC. The association of clinical outcome to front-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC) patients (Pts). J Clin Oncol. 2011; 29 (suppl; abstr 4555).

    Google Scholar 

  7. Escudier B, Loomis AK, Kaprin A, Motzer R, Tomczak P, Tarazi J, Kim S, Gao F, Williams JA, Rini B. Association of single nucleotide polymorphisms (SNPs) in VEGF pathway genes with progression-free survival (PFS) and blood pressure (BP) in metastatic renal cell carcinoma (mRCC) in the phase 3 trial of axitinib versus sorafenib (AXIS trial). Eur J Cancer. 2011;47(Suppl 1):S505.

    Article  Google Scholar 

Download references

Acknowledgments

The RENIS database is maintained with partial support by Pfizer and Bayer Schering Pharma, the manufacturers of sunitinib and sorafenib, respectively.

Conflict of interest

TB and BM have received honoraria for lectures from Pfizer and Bayer Schering Pharma.

Author information

Authors and Affiliations

  1. Department of Oncology, First Faculty of Medicine, Thomayer Hospital and Charles University, Videnska 800, 140 59, Prague, Czech Republic

    Tomas Buchler & Jitka Abrahamova

  2. Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic

    Tomas Pavlik & Zbynek Bortlicek

  3. Department of Complex Oncology Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic

    Alexandr Poprach & Rostislav Vyzula

  4. Department of Oncology, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic

    Bohuslav Melichar

Authors
  1. Tomas Buchler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tomas Pavlik
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zbynek Bortlicek
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alexandr Poprach
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rostislav Vyzula
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jitka Abrahamova
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Bohuslav Melichar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tomas Buchler.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Buchler, T., Pavlik, T., Bortlicek, Z. et al. Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma. Med Oncol 29, 3321–3324 (2012). https://doi.org/10.1007/s12032-012-0293-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-012-0293-x

Keywords

Search

Navigation